Mostrar el registro sencillo del ítem
dc.contributor.author
González, Germán Esteban
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.contributor.author
Rhaleb, Nour Eddine
dc.contributor.author
D'Ambrosio, Martin A.
dc.contributor.author
Nakagawa, Pablo
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.contributor.author
Liu, Yunhe
dc.contributor.author
Leung, Pablo
dc.contributor.author
Dai, Xiangguo
dc.contributor.author
Yang, Xiao Ping
dc.contributor.author
Peterson, Edward L.
dc.contributor.author
Carretero, Oscar A.
dc.date.available
2020-02-20T21:58:41Z
dc.date.issued
2015-01
dc.identifier.citation
González, Germán Esteban; Rhaleb, Nour Eddine; D'Ambrosio, Martin A.; Nakagawa, Pablo; Liu, Yunhe; et al.; Deletion of interleukin-6 prevents cardiac inflammation, fibrosis and dysfunctionwithout affecting blood pressure in angiotensin II-high salt-induced hypertension; Lippincott Williams; Journal of Hypertension; 33; 1; 1-2015; 144-152
dc.identifier.issn
0263-6352
dc.identifier.uri
http://hdl.handle.net/11336/98221
dc.description.abstract
Objective: Inflammation has been proposed as a key component in the development of hypertension and cardiac remodeling associated with different cardiovascular diseases. However, the role of the proinflammatory cytokine interleukin-6 in the chronic stage of hypertension is not well defined. Here, we tested the hypothesis that deletion of interleukin-6 protects against the development of hypertension, cardiac inflammation, fibrosis, remodeling and dysfunction induced by high salt diet and angiotensin II (Ang II). Methods: Male C57BL/6J and interleukin-6-knock out (KO) mice were implanted with telemetry devices for blood pressure (BP) measurements, fed a 4% NaCl diet, and infused with either vehicle or Ang II (90 ng/min per mouse subcutaneously) for 8 weeks. We studied BP and cardiac function by echocardiography at baseline, 4 and 8 weeks. Results: Myocyte cross-sectional area (MCSA), macrophage infiltration, and myocardial fibrosis were also assessed. BP increased similarly in both strains when treated with Ang II and high salt (Ang II-high salt); however, C57BL/6J mice developed a more severe decrease in left ventricle ejection fraction, fibrosis, and macrophage infiltration compared with interleukin-6-KO mice. No differences between strains were observed in MCSA, capillary density and MCSA to capillary density ratio. Conclusion: In conclusion, absence of interleukin -6 did not alter the development of Ang II-high salt-induced hypertension and cardiac hypertrophy, but it prevented the development of cardiac dysfunction, myocardial inflammation, and fibrosis. This indicates that interleukin-6 plays an important role in hypertensive heart damage but not in the development of hypertension.
dc.format
application/pdf
dc.language.iso
eng
dc.publisher
Lippincott Williams
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.rights
info:eu-repo/semantics/openAccess
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.subject
ANGIOTENSIN II
dc.subject
HEART FAILURE
dc.subject
HYPERTENSION
dc.subject
INTERLEUKIN 6
dc.subject.classification
Patología
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.subject.classification
Medicina Básica
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.title
Deletion of interleukin-6 prevents cardiac inflammation, fibrosis and dysfunctionwithout affecting blood pressure in angiotensin II-high salt-induced hypertension
dc.type
info:eu-repo/semantics/article
dc.type
info:ar-repo/semantics/artículo
dc.type
info:eu-repo/semantics/publishedVersion
dc.date.updated
2019-12-27T14:06:11Z
dc.journal.volume
33
dc.journal.number
1
dc.journal.pagination
144-152
dc.journal.pais
Estados Unidos
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.description.fil
Fil: González, Germán Esteban. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Fisiopatología Cardiovascular; Argentina. Henry Ford Hospital; Estados Unidos. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
dc.description.fil
Fil: Rhaleb, Nour Eddine. Henry Ford Hospital; Estados Unidos
dc.description.fil
Fil: D'Ambrosio, Martin A.. Henry Ford Hospital; Estados Unidos
dc.description.fil
Fil: Nakagawa, Pablo. Henry Ford Hospital; Estados Unidos
dc.description.fil
Fil: Liu, Yunhe. Henry Ford Hospital; Estados Unidos
dc.description.fil
Fil: Leung, Pablo. Henry Ford Hospital; Estados Unidos
dc.description.fil
Fil: Dai, Xiangguo. Henry Ford Hospital; Estados Unidos
dc.description.fil
Fil: Yang, Xiao Ping. Henry Ford Hospital; Estados Unidos. Wayne State University; Estados Unidos
dc.description.fil
Fil: Peterson, Edward L.. Henry Ford Hospital; Estados Unidos
dc.description.fil
Fil: Carretero, Oscar A.. Henry Ford Hospital; Estados Unidos
dc.journal.title
Journal of Hypertension
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1097/HJH.0000000000000358
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://insights.ovid.com/article/00004872-201501000-00018
Archivos asociados